<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764007</url>
  </required_header>
  <id_info>
    <org_study_id>16-19297</org_study_id>
    <nct_id>NCT03764007</nct_id>
  </id_info>
  <brief_title>18F-Fluorocholine for the Detection of Parathyroid Adenomas</brief_title>
  <official_title>18F-Fluorocholine for the Detection of Parathyroid Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying the ability of F18 labeled fluorocholine PET to localize
      parathyroid adenomas in patients with hyperparathyroidism prior to surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for the detection of the abnormal parathyroid adenoma.</measure>
    <time_frame>Through time of parathyroidectomy, an average of 1 year</time_frame>
    <description>Sensitivity of imaging in comparison to pathology at surgery. Location of parathyroid adenoma at imaging as read by three blinded readers, will be correlated to the location at surgery. True positive will be defined as an adenoma on imaging in the same location as seen at surgery. Sensitivity will be reported by individual reader.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hyperparathyroidism, Primary</condition>
  <arm_group>
    <arm_group_label>Fluorocholine PET arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a single fluorocholine PET imaging study prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorocholine PET</intervention_name>
    <description>Imaging study using PET after the injection of the fluorocholine radio tracer</description>
    <arm_group_label>Fluorocholine PET arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemically proven hyperparathyroidism and an indication for surgery

          -  Age â‰¥ 13 years

          -  Karnofsky performance status of &gt; 50 (or ECOG/WHO equivalent).

          -  Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria:

          -  Patients exceeding the weight limitations of the scanner or are not able to enter the
             bore of the PET scanner due to BMI.

          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
             etc.).

          -  Inability to complete the needed investigational due to other reasons (severe
             claustrophobia, radiation phobia, etc.).

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Insoo Soo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Aslam</last_name>
    <email>maya.aslam@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Imaging Center at China Basin</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hope, MD</last_name>
      <email>thomas.hope@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

